Abstracts
Abstract
Background Negative symptoms (NS) of schizophrenia, including avolition, anergia, and social withdrawal cause major functional impairment and have limited treatment options. Repetitive transcranial magnetic stimulation (rTMS) targeting the left dorsolateral prefrontal cortex (LDLPFC) shows promise in alleviating NS, though response remains modest, and multi-week protocols are often burdensome. A five-day, high-dose intermittent theta burst stimulation (iTBS) protocol using fMRI-guided neuronavigation has demonstrated rapid and sustained effects in major depression. Given the overlap between depressive lassitude and NS domains, accelerated neuronavigated iTBS may hold promise in schizophrenia with NS.
Methods This multisite, randomized, patient- and rater-blinded trial evaluates the feasibility, safety, and preliminary efficacy of such a protocol in individuals with schizophrenia spectrum disorders. Seventy-five adults with clinically significant NS will receive either: (1) neuronavigated active iTBS targeting LDLPFC regions most anti-correlated with the subgenual anterior cingulate cortex (sgACC) (2) non-neuronavigated active iTBS using scalp-based coordinates; or (3) neuronavigated sham stimulation over 10 daily sessions spanning 5 consecutive days (90,000 pulses total), with follow-ups at 1 week, 1 month, and 3 months.
Résultats Outcomes include a reduction in NS; Efficacy comparisons between neuronavigation and non-neuronavigation; Feasibility and safety; Change in social and affective information processing; Change in depressive symptoms.
Conclusion Results will inform future trials, while comparison of targeting strategies will clarify the utility of neuronavigation. If successful, this trial will offer a time-efficient, personalized intervention for NS.
Keywords:
- schizophrenia,
- negative symptoms,
- neuromodulation,
- neuronavigation
Résumé
Contexte Les symptômes négatifs (SN) de la schizophrénie, notamment l’avolition, l’anergie et le retrait social, entraînent des troubles fonctionnels majeurs et ne disposent que d’options thérapeutiques limitées. La stimulation magnétique transcrânienne répétitive (rTMS) ciblant le cortex préfrontal dorsolatéral gauche (LDLPFC) semble prometteuse pour atténuer les SN, bien que la réponse reste modeste et que les protocoles s’étalant sur plusieurs semaines soient souvent contraignants. Un protocole de stimulation intermittente à salves thêta (iTBS) à haute dose sur cinq jours, utilisant une neuronavigation guidée par IRMf, a démontré des effets rapides et durables dans la dépression majeure. Compte tenu du chevauchement entre la lassitude dépressive et les domaines des SN, une iTBS accélérée avec neuronavigation pourrait s’avérer prometteuse dans la schizophrénie avec SN.
Méthodes Cet essai multicentrique, randomisé, en double aveugle (tant pour les patients que pour les évaluateurs) évalue la faisabilité, la sécurité et l’efficacité préliminaire d’un tel protocole chez des personnes atteintes de troubles du spectre schizophrénie. Soixante-quinze adultes présentant des SN cliniquement significatifs recevront soit : (1) une iTBS active guidée par neuronavigation ciblant les régions du LDLPFC les plus anticorrélées avec le cortex cingulaire antérieur sous-génual (sgACC) ; (2) une iTBS active sans neuronavigation utilisant des coordonnées du cuir chevelu standardisées ; ou (3) une stimulation simulée avec neuronavigation, administrée à raison de 10 séances quotidiennes pendant 5 jours consécutifs (90 000 impulsions au total), avec des suivis à 1 semaine, 1 mois et 3 mois. Les critères d’évaluation incluent la réduction des SN ; des comparaisons d’efficacité entre la neuronavigation et la non-neuronavigation ; la faisabilité et la sécurité ; changements dans le traitement de l’information sociale et affective et dans les symptômes dépressifs.
Résultats les résultats attendus comprennent une réduction de la NS ; des comparaisons d’efficacité entre la neuronavigation et les techniques sans neuronavigation ; l’évaluabilité et la sécurité ; l’évolution du traitement de l’information sociale et affective ; l’évolution des symptômes dépressifs.
Conclusion les résultats serviront de base à de futurs essais, tandis que la comparaison des stratégies de ciblage permettra de clarifier l’utilité de la neuronavigation. En cas de succès, cet essai proposera une intervention personnalisée et rapide pour la NS
Mots-clés :
- schizophrénie,
- symptômes négatifs,
- neuromodulation,
- neuronavigation
Appendices
Bibliography
- Adams, R. et David, A. S. Patterns of anterior cingulate activation in schizophrenia: a selective review. Neuropsychiatr. Dis. Treat. 3, 87-101 (2007).
- Andreasen, N. C. et al. Remission in schizophrenia: proposed criteria and rationale for consensus. Am. J. Psychiatry 162, 441-449 (2005).
- Barreiros, A. R. et al. Intra- and Inter-Network connectivity of the default mode network differentiates Treatment-Resistant depression from Treatment-Sensitive depression. NeuroImage Clin. 43, 103656 (2024).
- Beam, W., Borckardt, J. J., Reeves, S. T. et George, M. S. (2009). An efficient and accurate new method for locating the F3 position for prefrontal TMS applications. Brain Stimulation, 2(1), 50-54.
- Benrimoh, D., Fisher, V. L., Seabury, R., Sibarium, E., Mourgues, C., Chen, D. et Powers, A. (2023). Evidence for Reduced Sensory Precision and Increased Reliance on Priors in Hallucination-Prone Individuals in a General Population Sample. Schizophrenia Bulletin. https://doi.org/10.1093/schbul/sbad136
- Bluhm, R. L., Osuch, E. A., Lanius, R. A., Boksman, K., Neufeld, R. W. J., Théberge, J. et Williamson, P. (2008). Default mode network connectivity: effects of age, sex, and analytic approach. Neuroreport, 19(8), 887-891.
- Bodapati, A. S. et Herbener, E. S. (2014). The impact of social content and negative symptoms on affective ratings in schizophrenia. Psychiatry Research, 218(1-2), 25-30.
- Cash, R. F. H. (2021). Personalized connectivity-guided DLPFC-TMS for depression: Advancing computational feasibility, precision and reproducibility. Hum. Brain Mapp, 42, 4155-4172.
- Cerveri, G., Gesi, C. et Mencacci, C. (2019). Pharmacological treatment of negative symptoms in schizophrenia: update and proposal of a clinical algorithm. Neuropsychiatric Disease and Treatment, 15, 1525-1535.
- Cole, E. J., Phillips, A. L., Bentzley, B. S., Stimpson, K. H., Nejad, R., Barmak, F., Veerapal, C., Khan, N., Cherian, K., Felber, E., Brown, R., Choi, E., King, S., Pankow, H., Bishop, J. H., Azeez, A., Coetzee, J., Rapier, R., Odenwald, N., … Williams, N. R. (2022). Stanford Neuromodulation Therapy (SNT): A Double-Blind Randomized Controlled Trial. The American Journal of Psychiatry, 179(2), 132-141.
- Cole, E. J., Stimpson, K. H., Bentzley, B. S., Gulser, M., Cherian, K., Tischler, C., Nejad, R., Pankow, H., Choi, E., Aaron, H., Espil, F. M., Pannu, J., Xiao, X., Duvio, D., Solvason, H. B., Hawkins, J., Guerra, A., Jo, B., Raj, K. S., … Williams, N. R. (2020). Stanford Accelerated Intelligent Neuromodulation Therapy for Treatment-Resistant Depression. The American Journal of Psychiatry, 177(8), 716-726.
- Connolly, C. G., Wu, J., Ho, T. C., Hoeft, F., Wolkowitz, O., Eisendrath, S., Frank, G., Hendren, R., Max, J. E., Paulus, M. P., Tapert, S. F., Banerjee, D., Simmons, A. N. et Yang, T. T. (2013). Resting-state functional connectivity of subgenual anterior cingulate cortex in depressed adolescents. Biological Psychiatry, 74(12), 898-907.
- Correll, C. U. et Schooler, N. R. (2020). Negative symptoms in schizophrenia: A review and clinical guide for recognition, assessment, and treatment. Neuropsychiatric Disease and Treatment, 16, 519-534.
- Crowe, M., Inder, M. et Porter, R. (2015). Conducting qualitative research in mental health: Thematic and content analyses. The Australian and New Zealand Journal of Psychiatry, 49(7), 616-623.
- Diaconescu, A. O., Wellstein, K. V., Kasper, L., Mathys, C. et Stephan, K. E. (2020). Hierarchical Bayesian models of social inference for probing persecutory delusional ideation. Journal of Abnormal Psychology, 129(6), 556-569.
- Fox, M. D., Buckner, R. L., White, M. P., Greicius, M. D. et Pascual-Leone, A. (2012). Efficacy of transcranial magnetic stimulation targets for depression is related to intrinsic functional connectivity with the subgenual cingulate. Biological Psychiatry, 72(7), 595-603.
- Han, Y., Jin, F., Lee, J., Hou, W., Yang, X., Zhang, Y., Zhang, Y., Lu, X., Wang, Z., Bo, Q., Yang, Z., Zhou, F., Jiang, T. et Wang, C. (2025). Accelerated iTBS with a personalised targeting method to treat negative symptoms of schizophrenia: A randomized controlled trial. Brain Stimulation, 18(3), 710-719.
- Hauke, D. J., Wobmann, M., Andreou, C., Mackintosh, A. J., de Bock, R., Karvelis, P., Adams, R. A., Sterzer, P., Borgwardt, S., Roth, V. et Diaconescu, A. O. (2024). Altered perception of environmental volatility during social learning in emerging psychosis. Computational Psychiatry (Cambridge, Mass.), 8(1), 1-22.
- He, H., Liu, Q., Li, N., Guo, L., Gao, F., Bai, L., Gao, F. et Lyu, J. (2020). Trends in the incidence and DALYs of schizophrenia at the global, regional and national levels: results from the Global Burden of Disease Study 2017. Epidemiology and Psychiatric Sciences, 29(e91), e91.
- Hu, M.-L. et al. A review of the functional and anatomical default mode network in schizophrenia. Neurosci. Bull. 33, 73-84 (2017).
- Iversen, T. S. J., Steen, N. E., Dieset, I., Hope, S., Mørch, R., Gardsjord, E. S., Jørgensen, K. N., Melle, I., Andreassen, O. A., Molden, E. et Jönsson, E. G. (2018). Side effect burden of antipsychotic drugs in real life—Impact of gender and polypharmacy. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 82, 263-271.
- Kaster, T. S., Downar, J., Vila-Rodriguez, F., Baribeau, D. A., Thorpe, K. E., Daskalakis, Z. J. et Blumberger, D. M. (2023). Differential symptom cluster responses to repetitive transcranial magnetic stimulation treatment in depression. EClinicalMedicine, 55(101765), 101765.
- Kirkpatrick, B., Fenton, W. S., Carpenter, W. T., Jr et Marder, S. R. (2006). The NIMH-MATRICS consensus statement on negative symptoms. Schizophrenia Bulletin, 32(2), 214-219.
- Kirschner, M., Schmidt, A., Hodzic-Santor, B., Burrer, A., Manoliu, A., Zeighami, Y., Yau, Y., Abbasi, N., Maatz, A., Habermeyer, B., Abivardi, A., Avram, M., Brandl, F., Sorg, C., Homan, P., Riecher-Rössler, A., Borgwardt, S., Seifritz, E., Dagher, A., . . . Kaiser, S. (2021). Orbitofrontal-Striatal Structural Alterations Linked to Negative Symptoms at Different Stages of the Schizophrenia Spectrum. Schizophrenia Bulletin, 47(3), 849-863. https://doi.org/10.1093/schbul/sbaa169
- Kumar, N., Vishnubhatla, S., Wadhawan, A. N., Minhas, S. et Gupta, P. (2020). A randomized, double blind, sham-controlled trial of repetitive transcranial magnetic stimulation (rTMS) in the treatment of negative symptoms in schizophrenia. Brain Stimulation, 13(3), 840-849.
- Laurens, K. R., Ngan, E. T. C., Bates, A. T., Kiehl, K. A. et Liddle, P. F. Rostral anterior cingulate cortex dysfunction during error processing in schizophrenia. Brain 126, 610-622 (2003).
- Liu, Y., Jalali, S., Joober, R., Lepage, M., Iyer, S., Shah, J. et Benrimoh, D. (2025). Subtyping first-episode psychosis based on longitudinal symptom trajectories using machine learning. Npj Mental Health Research, 4(1), 18.
- Lorentzen, R., Nguyen, T. D., McGirr, A., Hieronymus, F. et Østergaard, S. D. (2022). The efficacy of transcranial magnetic stimulation (TMS) for negative symptoms in schizophrenia: a systematic review and meta-analysis. Schizophrenia (Heidelberg, Germany), 8(1), 35.
- Mayberg, H. S. et al. Deep brain stimulation for treatment-resistant depression. Neuron 45, 651-660 (2005).
- McCutcheon, R. A., Abi-Dargham, A. et Howes, O. D. (2019). Schizophrenia, Dopamine and the Striatum: From Biology to Symptoms. Trends in Neurosciences, 42(3), 205. https://doi.org/10.1016/j.tins.2018.12.004
- Miron, J.-P., Jodoin, V. D., Lespérance, P. et Blumberger, D. M. (2021). Repetitive transcranial magnetic stimulation for major depressive disorder: basic principles and future directions. Therapeutic Advances in Psychopharmacology, 11, 20451253211042696.
- Morrissette, D. A. et Stahl, S. M. (2011). Affective symptoms in schizophrenia. Drug Discovery Today. Therapeutic Strategies, 8(1-2), 3-9.
- Overvliet, G. M., Jansen, R. A. C., van Balkom, A. J. L. M., van Campen, D. C., Oudega, M. L., van der Werf, Y. D., van Exel, E., van den Heuvel, O. A. et Dols, A. (2021). Adverse events of repetitive transcranial magnetic stimulation in older adults with depression, a systematic review of the literature. International Journal of Geriatric Psychiatry, 36(3), 383-392.
- Powers, A. R., Mathys, C. et Corlett, P. R. (2017). Pavlovian conditioning-induced hallucinations result from overweighting of perceptual priors. Science, 357(6351), 596-600.
- Rabinowitz, J. (2018). Treating negative symptoms of schizophrenia: Few pharmacologic options, but evidence supports combining psychosocial interventions. Current Psychiatry, 17(12), 19-22.
- Ramirez-Mahaluf, J. P., Roxin, A., Mayberg, H. S. et Compte, A. A Computational Model of Major Depression: the Role of Glutamate Dysfunction on Cingulo-Frontal Network Dynamics. Cereb. Cortex 27, 660-679 (2017).
- Robison AJ, Thakkar KN, Diwadkar VA. Cognition and Reward Circuits in Schizophrenia: Synergistic, Not Separate. Biol Psychiatry. 2020 Feb 1;87(3):204-214. doi: 10.1016/j.biopsych.2019.09.021.
- Saleh, Y., Jarratt-Barnham, I., Fernandez-Egea, E. et Husain, M. (2021). Mechanisms Underlying Motivational Dysfunction in Schizophrenia. Frontiers in Behavioral Neuroscience, 15, 709753. https://doi.org/10.3389/fnbeh.2021.709753
- Schiena, G. et al. Connectivity changes in major depressive disorder after rTMS: a review of functional and structural connectivity data. Epidemiol. Psychiatr. Sci. 30, e59 (2021).
- Stevens, F. L., Hurley, R. A. et Taber, K. H. (2011). Anterior cingulate cortex: unique role in cognition and emotion. The Journal of Neuropsychiatry and Clinical Neurosciences, 23(2), 121-125.
- Thibaudeau, E., Sauve, G., Lavigne, K. et Raucher-Chéné, D. (2023). Open Cognitive Battery. OSF.
- Unrau, J. et al. Subtyping negative symptoms in first-episode psychosis: Contrasting persistent negative symptoms with a data-driven approach. Schizophr. Res. 248, 219-227 (2022).
- Van der Vaart, A. TMS in Schizophrenia: Potential Mechanistic Insights via Resting-State Network Analyses. Current Behavioral Neuroscience Reports 10, 58-63 (2023).
- Wang, X., Chang, Z. et Wang, R. Opposite effects of positive and negative symptoms on resting-state brain networks in schizophrenia. Commun. Biol. 6, 279 (2023)
- Wang, X.-Y., Zhang, Y.-B., Mu, R.-X., Cui, L.-B. et Wang, H.-N. (2024). Repetitive transcranial magnetic stimulation enhanced by neuronavigation in the treatment of depressive disorder and schizophrenia. World Journal of Psychiatry, 14(11), 1618-1622.
- Williams, J. B. W. et Kobak, K. A. (2008). Development and reliability of a structured interview guide for the Montgomery-Åsberg Depression Rating Scale (SIGMA). The British Journal of Psychiatry: The Journal of Mental Science, 192(1), 52-58.
- Zeng, J., Yan, J., Cao, H. et al. Neural substrates of reward anticipation and outcome in schizophrenia: a meta-analysis of fMRI findings in the monetary incentive delay task. Transl Psychiatry 12, 448 (2022). https://doi.org/10.1038/s41398-022-02201-8

